OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status
Hilda Ferrero, Maite Solas, Paul T. Francis, et al.
CNS Drugs (2016) Vol. 31, Iss. 1, pp. 19-32
Closed Access | Times Cited: 93
Hilda Ferrero, Maite Solas, Paul T. Francis, et al.
CNS Drugs (2016) Vol. 31, Iss. 1, pp. 19-32
Closed Access | Times Cited: 93
Showing 1-25 of 93 citing articles:
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser, Misty M. Attwood, Mathias Rask‐Andersen, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 12, pp. 829-842
Open Access | Times Cited: 2290
Alexander S. Hauser, Misty M. Attwood, Mathias Rask‐Andersen, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 12, pp. 829-842
Open Access | Times Cited: 2290
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress
Zhipei Sang, Keren Wang, Jianghong Dong, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114464-114464
Closed Access | Times Cited: 88
Zhipei Sang, Keren Wang, Jianghong Dong, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114464-114464
Closed Access | Times Cited: 88
Slow-Wave Activity Enhancement to Improve Cognition
Kristine A. Wilckens, Fabio Ferrarelli, Matthew P. Walker, et al.
Trends in Neurosciences (2018) Vol. 41, Iss. 7, pp. 470-482
Open Access | Times Cited: 107
Kristine A. Wilckens, Fabio Ferrarelli, Matthew P. Walker, et al.
Trends in Neurosciences (2018) Vol. 41, Iss. 7, pp. 470-482
Open Access | Times Cited: 107
G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits
Shofiul Azam, Md. Ezazul Haque, Md. Jakaria, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 506-506
Open Access | Times Cited: 101
Shofiul Azam, Md. Ezazul Haque, Md. Jakaria, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 506-506
Open Access | Times Cited: 101
The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update
Rita Khoury, Noam Grysman, Jake Gold, et al.
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 6, pp. 523-533
Closed Access | Times Cited: 98
Rita Khoury, Noam Grysman, Jake Gold, et al.
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 6, pp. 523-533
Closed Access | Times Cited: 98
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease
Luke Whiley, Katie E. Chappell, Ellie D’Hondt, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 93
Luke Whiley, Katie E. Chappell, Ellie D’Hondt, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 93
Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands
Laura Blaikie, Graeme Kay, Paul Kong Thoo Lin
MedChemComm (2019) Vol. 10, Iss. 12, pp. 2052-2072
Open Access | Times Cited: 85
Laura Blaikie, Graeme Kay, Paul Kong Thoo Lin
MedChemComm (2019) Vol. 10, Iss. 12, pp. 2052-2072
Open Access | Times Cited: 85
Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
Juan F. González, Andrés R. Alcántara, A. Doadrio, et al.
Expert Opinion on Drug Discovery (2019) Vol. 14, Iss. 9, pp. 879-891
Closed Access | Times Cited: 81
Juan F. González, Andrés R. Alcántara, A. Doadrio, et al.
Expert Opinion on Drug Discovery (2019) Vol. 14, Iss. 9, pp. 879-891
Closed Access | Times Cited: 81
Antagonism of the 5-HT 6 receptor – Preclinical rationale for the treatment of Alzheimer's disease
Inge E.M. de Jong, Arne Mørk
Neuropharmacology (2017) Vol. 125, pp. 50-63
Closed Access | Times Cited: 70
Inge E.M. de Jong, Arne Mørk
Neuropharmacology (2017) Vol. 125, pp. 50-63
Closed Access | Times Cited: 70
Serotonergic Control of Metabolic Homeostasis
Steven C. Wyler, Caleb C. Lord, Syann Lee, et al.
Frontiers in Cellular Neuroscience (2017) Vol. 11
Open Access | Times Cited: 69
Steven C. Wyler, Caleb C. Lord, Syann Lee, et al.
Frontiers in Cellular Neuroscience (2017) Vol. 11
Open Access | Times Cited: 69
Role of green tea catechins in prevention of age‐related cognitive decline: Pharmacological targets and clinical perspective
Mohammad Hosein Farzaei, Roodabeh Bahramsoltani, Zahra Abbasabadi, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 3, pp. 2447-2459
Closed Access | Times Cited: 64
Mohammad Hosein Farzaei, Roodabeh Bahramsoltani, Zahra Abbasabadi, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 3, pp. 2447-2459
Closed Access | Times Cited: 64
Constitutive activity of 5-HT receptors: Factual analysis
Philippe De Deurwaerdère, Rahul Bharatiya, Abdeslam Chagraoui, et al.
Neuropharmacology (2020) Vol. 168, pp. 107967-107967
Open Access | Times Cited: 52
Philippe De Deurwaerdère, Rahul Bharatiya, Abdeslam Chagraoui, et al.
Neuropharmacology (2020) Vol. 168, pp. 107967-107967
Open Access | Times Cited: 52
Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates
Monika Marcinkowska, Joanna Śniecikowska, Nikola Fajkis, et al.
CNS Drugs (2020) Vol. 34, Iss. 3, pp. 243-268
Open Access | Times Cited: 52
Monika Marcinkowska, Joanna Śniecikowska, Nikola Fajkis, et al.
CNS Drugs (2020) Vol. 34, Iss. 3, pp. 243-268
Open Access | Times Cited: 52
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)
Martina Bortolami, Daniele Rocco, Antonella Messore, et al.
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 5, pp. 399-420
Closed Access | Times Cited: 46
Martina Bortolami, Daniele Rocco, Antonella Messore, et al.
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 5, pp. 399-420
Closed Access | Times Cited: 46
Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights
Najmeh Oliyaei, Marzieh Moosavi‐Nasab, Nader Tanideh, et al.
Brain Research Bulletin (2022) Vol. 193, pp. 11-21
Open Access | Times Cited: 38
Najmeh Oliyaei, Marzieh Moosavi‐Nasab, Nader Tanideh, et al.
Brain Research Bulletin (2022) Vol. 193, pp. 11-21
Open Access | Times Cited: 38
Rational drug design strategies for the development of promising multi-target directed indole hybrids as Anti-Alzheimer agents
Namy George, Md Jawaid Akhtar, Khalid Al Balushi, et al.
Bioorganic Chemistry (2022) Vol. 127, pp. 105941-105941
Closed Access | Times Cited: 30
Namy George, Md Jawaid Akhtar, Khalid Al Balushi, et al.
Bioorganic Chemistry (2022) Vol. 127, pp. 105941-105941
Closed Access | Times Cited: 30
Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET
Rajiv Radhakrishnan, Nabeel Nabulsi, Edward Gaiser, et al.
Journal of Nuclear Medicine (2018) Vol. 59, Iss. 9, pp. 1445-1450
Open Access | Times Cited: 55
Rajiv Radhakrishnan, Nabeel Nabulsi, Edward Gaiser, et al.
Journal of Nuclear Medicine (2018) Vol. 59, Iss. 9, pp. 1445-1450
Open Access | Times Cited: 55
Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease
Anna Więckowska, Tomasz Wichur, Justyna Godyń, et al.
ACS Chemical Neuroscience (2018) Vol. 9, Iss. 5, pp. 1195-1214
Closed Access | Times Cited: 52
Anna Więckowska, Tomasz Wichur, Justyna Godyń, et al.
ACS Chemical Neuroscience (2018) Vol. 9, Iss. 5, pp. 1195-1214
Closed Access | Times Cited: 52
The 5-HT6 receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies
Séverine Chaumont‐Dubel, Vincent Dupuy, Joël Bockaert, et al.
Neuropharmacology (2019) Vol. 172, pp. 107839-107839
Open Access | Times Cited: 48
Séverine Chaumont‐Dubel, Vincent Dupuy, Joël Bockaert, et al.
Neuropharmacology (2019) Vol. 172, pp. 107839-107839
Open Access | Times Cited: 48
Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 8, pp. 823-842
Closed Access | Times Cited: 47
Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 8, pp. 823-842
Closed Access | Times Cited: 47
M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Miriam Scarpa, Sarah Hesse, Sophie J. Bradley
Advances in pharmacology (2020), pp. 277-310
Closed Access | Times Cited: 46
Miriam Scarpa, Sarah Hesse, Sophie J. Bradley
Advances in pharmacology (2020), pp. 277-310
Closed Access | Times Cited: 46
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?
Miloš Mitić, Tamara Lazarević‐Pašti
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 7, pp. 841-856
Closed Access | Times Cited: 34
Miloš Mitić, Tamara Lazarević‐Pašti
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 7, pp. 841-856
Closed Access | Times Cited: 34
Pathophysiologic Role of Neurotransmitters in Digestive Diseases
Xiaoxu Yang, Jun Lou, Weixi Shan, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 34
Xiaoxu Yang, Jun Lou, Weixi Shan, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 34
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
Ramakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 5, pp. 1843-1859
Closed Access | Times Cited: 42
Ramakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 5, pp. 1843-1859
Closed Access | Times Cited: 42
5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
Megan Andrews, Babak Tousi, Marwan N. Sabbagh
Neurology and Therapy (2018) Vol. 7, Iss. 1, pp. 51-58
Open Access | Times Cited: 41
Megan Andrews, Babak Tousi, Marwan N. Sabbagh
Neurology and Therapy (2018) Vol. 7, Iss. 1, pp. 51-58
Open Access | Times Cited: 41
